COM(2022)721 EU - Regulation
Fees and charges payable to the European Medicines Agency

Please note

This page contains a limited version of this dossier in the Parlementaire Monitor.

Contents

  1. Key information
  2. Key dates
  3. Related information
  4. Resulting legislation
  5. Full version
  6. EU Monitor

1.

Key information

official title

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on fees and charges payable to the European Medicines Agency, amending Regulation (EU) 2017/745 of the European Parliament and of the Council and repealing Council Regulation (EC) No 297/95 and Regulation (EU) 658/2014 of the European Parliament and of the Council
 
Legal instrument Regulation
Decision making procedure ordinary legislative procedure (COD)
reference by COM-number i COM(2022)721 EN
Additional COM-numbers SEC(2022)440; SWD(2022)413; SWD(2022)414; SWD(2022)415
procedure number i 2022/0417(COD)
CELEX number i 52022PC0721

2.

Key dates

Document 13-12-2022
Online publication 13-12-2022
Decision 07-02-2024; Verordening 2024/568

3.

Related information

4.

Resulting legislation

 

5.

Full version

This page is also available in a full version containing the latest state of affairs, the summary of the European Parliament Legislative Observatory, the legal context, other dossiers related to the dossier at hand, the stakeholders involved (e.g. European Commission directorates-general, European Parliament committees, Council configurations and even individual EU Commissioners and Members of the European Parliament) and finally documents of the European Parliament, the Council of Ministers and the European Commission.

The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.

6.

EU Monitor

The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.